Bohring-Opitz Syndrome for the Purpose of a Case and Review of the Topic

Authors

  • Daniela Alejandra Tolosa Quintero

  • Carolina Rivera Nieto

  • Juan Sebastián Leguizamón Melo

Keywords:

Bohring Opitz Syndrome, ASXL1, HOX genes, BOPS

Abstract

The Bohring-Opitz syndrome (BOPS) was first described in 1999 by Bohring et al (1). It is an extremely rare genetic condition, of unknown prevalence, which is caused by de novo or nonsense mutations in the ASXL1 gene. To date 46 people with BOPS have been described, of whom only 20 have a confirmed molecular diagnosis. The BOPS diagnosis is established by clinical suspicion and / or identification of a constitutional heterozygous pathogenic variant in the ASXL1 gene (2). This article shows the first case in Latin America of BOPS confirmed by molecular diagnosis.

How to Cite

Bohring-Opitz Syndrome for the Purpose of a Case and Review of the Topic. (2019). Global Journal of Medical Research, 19(6), 7-11. https://medicalresearchjournal.org/index.php/GJMR/article/view/1704

References

Hastings R, Cobben J, Gillessen-kaesbach G, Goodship J, Hove H, Kjaergaard S (2011) Bohring - Opitz (Oberklaid - Danks) syndrome : clinical study, review of the literature , and discussion of possible pathogenesis. (September 2010), 513-9.

Tan Russell B, Graham M (2018) Bohring-Opitz Syndrome. http://www.ncbi.nlm.nih.gov/pubmed/29446906

Hoischen A, van BWM, Rodríguez-Santiago B, Gilissen C, Vissers LELM, de P (2011) Hoischen A, van Bon BWM, Rodríguez-Santiago B, Gilissen C, Vissers LELM, de Vries P, et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. 43(8), 729-731. http://www.nature.com/articles/ng.868

(2015) Bohring - Opitz Syndrome (BOS) with a New ASXL1 Pathogenic Variant : Review of the Most Prevalent Molecular and Phenotypic Features of the Syndrome.

Magini P, Monica Della, Luisa M, Uzielli G, Mongelli P, Scarselli G (2012) Two Novel Patients With Bohring - Opitz Syndrome Caused by De Novo ASXL1 Mutations.

G. Gillessen-kaesbach, Bohring - Opitz (2014) Oberklaid - Danks) syndrome: Clinical study, review of the literature, and discussion of possible pathogenesis.

G. Oudesluijs, D. Grange, A. Bohring, G. Zampino, P. Thierry (2006) New Cases of Bohring - Opitz Syndrome, Update, and Critical Review of the Literature. 1263, 1257-63.

Schenck Kleefstra T, Kramer M, Bokhoven Van (2014) Neuropharmacology The genetics of cognitive epigenetics Neuropharmacology. 80, 83-94.

Simpson ARH, Gibbon CEA, Quinn G, Turnpenny D (2007) Infantile high myopia in Bohring-Opitz syndrome. 11(5), 524-525.

Russell B, Johnston J, Biesecker G, Kramer N, Pickart A, Rhead W (2015) Clinical Management of Patients with ASXL1 Mutations and Bohring - Opitz Syndrome , Emphasizing the Need for Wilms Tumor Surveillance. (April), 2122-31.

Zhou Sheng M-Y, Yang Xu M-J (2014) [Role of ASXL1 mutation in myeloid malignancies]. 22(4), 1183-7.

Carlston M, O'Donnell-Luria H, Underhill R, Cummings B, Weisburd B, Minikel V (2017) Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome. 38(5), 517-523.

Bohring-Opitz Syndrome for the Purpose of a Case and  Review of the Topic

Published

2019-02-21

How to Cite

Bohring-Opitz Syndrome for the Purpose of a Case and Review of the Topic. (2019). Global Journal of Medical Research, 19(6), 7-11. https://medicalresearchjournal.org/index.php/GJMR/article/view/1704